Shares of large drugmakers such as Lilly, Gilead and J&J keep hitting record highs.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on MarketWatch ↗
Keywords
pharmaceuticalshealthcaretech stocksQQQ
Open a keyword to see other news on the same topic.
Related tickers and likely impact
QQQ
▼ Likely negativeInvesco QQQ Trust
Relevance: low
| Market | US stocks |
|---|---|
| Sector | ETF |
| Close on 10/29/2026 | 715.33 |
| Change that session | -1.42% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- What Just Happened To Alnylam Stock?
Alnylam Pharmaceuticals (ALNY) stock fell 25.1% on Thursday, October 29, 2026, the day it reported third-quarter results, while the S&P 500 slipped 0.3%. Revenue beat estimates at $1.46 billion versus $1.43 billion, with product revenue up 52% to about $1.3 billion led by AMVUTTRA, though GAAP net income of $2.2 billion included a one-time non-cash tax benefit of about $1.9 billion. Management said it is "not yet satisfied with the underlying demand growth" and expects TTR product sales at the low end of its $4.2 billion to $4.5 billion range. It also said turning new prescribers into patient starts is taking longer than hoped, and 2027 product revenue guidance will come in mid-February. The decline stood apart from a 2.4% rise in the health care fund XLV, and the stock is down 63.9% over the past twelve months.
- Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?
Teva shares have risen about 108% over the past 12 months as the company shifts toward branded drugs. Second-quarter sales of Ajovy, Uzedy and Austedo grew 56%, 43% and 40% year over year, and management raised full-year sales guidance for all three. Expected EPS is $2.11 in 2026 and $3.09 in 2027. Teva trades at around 13 times next year's earnings, and the author estimates that if 2030 EPS reaches about $4.10 and the valuation holds, the shares could rise moderately. Risks include a 38% price reduction for Austedo negotiated by CMS, effective January 2027.
- A pharma giant is moving past one patent cliff — but another is already looming
Novartis says remibrutinib, its experimental multiple sclerosis (MS) drug, could generate more than $4 billion in peak annual sales, even though Barclays recently cut its peak sales forecast after late-stage trials showed it reduced relapses by less than analysts expected. The drug belongs to the BTK inhibitor class and aims to regulate immune cell activity rather than eliminate cells, unlike Kesimpta, an anti-CD20 antibody. University of Pennsylvania MS specialist Amit Bar-Or said its safety profile looks promising but it is unlikely to control relapses as effectively as Kesimpta, and its biggest market-expansion opportunity could come from trials in progressive MS, with a readout expected in 2031. Morningstar analyst Jay Lee said the $4 billion-plus forecast is 'within the realm of possibility' but not de-risked. Meanwhile, the market is already looking to the next patent cliff around 2032 for Kisqali and Kesimpta, whose expiries alone represent $18 billion in peak sales.
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer
Reed Jobs, founder of oncology-focused venture capital firm Yosemite and son of Steve Jobs, told Fortune that GLP-1 drugs could be among the most important medicines to reach the market, with possible implications for cancer and cardiovascular disease. He called the GLP-1 revolution one of the biggest biotechnology developments of the past three years, while acknowledging drawbacks such as muscle loss. A JAMA Oncology study of 86,632 adults found GLP-1 users had a 17% lower hazard of developing the 14 cancers studied than nonusers, though the finding shows an association rather than proof that the drugs prevent cancer directly. Jobs said Yosemite's second fund exceeded its $350 million target and was oversubscribed, with AbbVie and Amgen among the investors. A Deloitte report found obesity drugs accounted for 25% of late-stage pipeline sales forecasts for major pharmaceutical companies, up from 1% in 2022.
- Novo Has Big Plans for 2030. Should You Buy the Stock Now?
Novo's shares have dropped more than 60% over the past couple of years as it lost market share in GLP-1 products such as Wegovy, Ozempic, and Rybelsus to Eli Lilly. Its 2030 goals include more than five products each generating several billion dollars in annual sales, revenue growth comparable to industry peers, serving 10 times as many obese patients with oral GLP-1 products, and reaching more than 60 million patients, up from over 45.6 million last year. Candidates such as CagriSema, awaiting approval after beating Wegovy in a head-to-head Phase 3 obesity study, and zenagamtide, in Phase 3 trials, are seen as having blockbuster potential. The author judges Novo fairly well-positioned to reach these goals, helped by licensed candidates such as UBT251 and HRS-1596, while the stock trades at about 12x forward earnings versus an average of 19.2x for healthcare stocks, though clinical setbacks remain a risk.
- Lilly’s Weight-Loss Machine Gets Even Bigger
Mounjaro and Zepbound once again drove a strong earnings beat for Lilly, along with a guidance upgrade worth billions of dollars. However, the company's new obesity pill is trailing Novo Nordisk from the start.
Related markets
Latest news
- The Gold-Silver Ratio Just Hit 80. Here's What History Says Happens Next.
The gold-silver ratio, the number of silver ounces needed to buy one ounce of gold, has reached 80 with gold at $3,919 and silver at $49 per ounce. The 80-50 rule of thumb calls 50–80 neutral, but its results have been mixed: the ratio fell to 46 on Jan. 29, 2026, its lowest since 2011, and silver bought at $49 last October would have more than doubled, beating gold's roughly 40% gain, though investors who later switched back to gold lost ground. The article notes that silver's dual role as a precious and industrial metal, with about 74% of output a byproduct of other mining, leaves it exposed to rising rates, the Iran war and inflation. It cites a silver deficit forecast to widen from 40.3 million ounces in 2025 to 46.3 million ounces in 2026. Even with silver cheaper on this measure, the author says the ratio does not necessarily signal the best time to invest.
- Alphabet's October wipeout hits $766 billion, its worst month ever
Alphabet (GOOGL) lost $477 billion in market value for the week through Friday's low, its worst week ever, after shares plunged $475 billion in one session on Thursday following third-quarter results. For October, the stock had shed about $766 billion at its low, second only to SpaceX's roughly $822 billion loss in July, and was down nearly 19% for the month, its steepest monthly drop since the 2004 IPO. Other megacaps also fell sharply, with Intel sliding as much as 30% after a weak outlook and Amazon losing about $70 billion for the week, while Eli Lilly, Tesla and SK Hynix added about $370 billion combined. UBS's chief investment office argued that retreating from markets does not protect portfolios and that investors should build resilient portfolios with exposure beyond tech. Alphabet closing at or below $280.50 on Friday would lock in its worst month since the IPO in percentage terms.
- Broadcom Stock Outlook Hinges On AI Chip Growth And Anthropic Partnership
Broadcom reported sharp growth in AI semiconductor revenue and expanded custom accelerator work with Anthropic and Meta, while its TrueSource Spring Enterprise release shipped 89 security fixes. The article says the outlook hinges on AI chip growth offsetting margin pressure, with Q4 2026 gross margin guided to 73% from 77.1% in Q2 2026 and about US$29b of potential exposure from AI XPV residual value guarantees. Analyst models assume revenue growth of about 52.7% a year and earnings rising from US$38.3b today to a consensus US$155.8b by 2029, implying a P/E of 23.0x versus 44.3x now. The consensus price target of US$531.85 sits above the current US$355.10 share price, though individual targets range from US$215.88 to US$715.00.
- Meta (META) Stock Sees Modest Fair Value Lift As Muse And Financing Drive Debate
The fair value estimate for Meta Platforms has risen from US$813.65 to US$848.38 per share as analysts weigh the Muse product ramp and a US$95b equity financing. Following Q3 results and the Muse launch, firms including Truist and Wells Fargo lifted targets to US$1,000, Tigress Financial to US$995 and Pivotal Research to US$960. Bulls cite strong advertising performance, early Muse engagement and possible new revenue from agents, business messaging and hardware. Bears such as Oppenheimer and Wedbush say Muse monetization may take time and that concerns about usage and password trust could limit willingness to pay, while Goldman Sachs and Oppenheimer flag higher 2027 operating expenses and capital spending. Mizuho and Piper Sandler note that the US$95b equity plan brings dilution into focus, though some interest expense could be reduced.
- Critical Metals Sinks 11% as European Lithium Deal Nears New Share Issuance; USA Rare Earth Tumbles 10%, MP Materials Falls 6%
Critical Metals fell 11% to $7.11 as new shares from its all-stock European Lithium acquisition are due to start trading on Nasdaq around November 6, with each European Lithium share converting into 0.045 of a Critical Metals share. The pre-revenue company expects full ownership of the Tanbreez rare earth project in Greenland and holds the Wolfsberg lithium project in Austria, but posted a net loss of $120.38 million for the six months to December 31, 2025 and has a going-concern warning. USA Rare Earth fell 10% to $9.52 and MP Materials dropped 6% to $39.21, with MP's Q2 2026 revenue up 89% to $108.49 million while USA Rare Earth posted Q2 2026 revenue of $5.82 million and a gross loss of $1.58 million. The article links the declines to a risk-off day in which the Invesco QQQ Trust fell 4% after big tech earnings, which hit volatile small and mid-cap stocks hardest. Both rare earth names have earnings reports coming up.
- Binance hack: Investigators in a 'cat and mouse game' to recover $6.3 billion in stolen funds
Crypto firms and law enforcement are racing to recover more than $6 billion in cryptocurrency stolen from Binance, which says its Secure Asset Fund for Users will cover losses. TRM Labs and Chainalysis have attributed the hack to the North Korea-linked group TraderTraitor, and stablecoin issuers such as Circle and Tether have frozen around $3 billion so far. The hackers reportedly sold USDT and borrowed ether against it, since ether is harder to freeze, and moved funds back and forth between wallets and to Tron addresses to obscure their trail. Investigators also see growing use of professional money laundering networks linked to China, which buy crypto off-chain and return it as stablecoins or fiat, making recovery harder the further funds travel. Chainalysis says it now has automated tools to track the funds, and TRM Labs says its tracing is improving.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.